

Supporting Information

Table S1. Information of the main chemicals used.

| Chemical names | Source | Catalog No. (CAT#) |
|--|------------------------------------|-----------------------|
| Collagen | Chrono-Log Corp. | 385 |
| ADP | Sigma Aldrich | A2754 |
| thrombin | Sigma Aldrich | T7009 |
| PAF | Sigma Aldrich | 511075 |
| SQ22536 | Sigma Aldrich | HY-100396 |
| TRAP (AYPGKF-NH ₂) | Peptides International | PAR-3674-PI |
| cAMP ELISA kit | Cayman Chemicals | 58100 |
| FITC-conjugated CD62P antibody | eBiosciences | MA5-16428 |
| FITC-conjugated CD63 antibody | eBiosciences | MA1-19602 |
| FITC-conjugated CD40L antibody | eBiosciences | 11-1548-42 |
| FITC-conjugated PAC-1 | eBiosciences | MA5-28564 |
| Alexa Fluor™ 488-conjugated fibrinogen | Thermo Fisher Scientific | F13191 |
| p-VASP ^{Ser157} antibody | Cell Signaling Technology | 84519 |
| β-actin antibody | Cell Signaling Technology | 3700 |
| GAPDH antibody | Cell Signaling Technology | 5174 |
| p-PKA substrate antibody | Cell Signaling Technology | 9624 |
| p-Erk1/2 ^{Thr202/Tyr204} antibody | Cell Signaling Technology | 4370 |
| p-Akt ^{Ser473} antibody | Cell Signaling Technology | 4060 |
| p-integrin β3 ^{Tyr773} antibody | ImmunoWay Biotechnology Company | YP0144 |
| Cangrelor | Selleck Chemical | S3737 |
| 740 Y-P | Selleck Chemical | S7865 |
| CytoPainter Phalloidin-IFluor 488 | Abcam | ab176753 |
| H89 | Abcam | ab143787 |
| LDH detection kit ^{PLUS} | Roche Applied Science | 04744926001 |




Figure S1. Chemical structures of 10 saponins in *Panax notoginseng* flowers (PNF). The major saponins of PNF (left), compounds (1)-(5), can be transformed to minor saponins of PNF (right), compounds (6)-(10), respectively, by selectively cleaving the β -(1 \rightarrow 2)-glucosidic linkage at position C-3 of ginsenosides, when PNF is extracted by water. G, Ginsenoside; GYP, Gypenoside; NG, Notoginsenoside; Glc, β -D-glucose.




Figure S2. G-Rb2 and G-Rd2 do not affect platelet aggregation in response to collagen, TRAP, thrombin, U46619, or PAF in human platelets *in vitro*. Human PRP were pre-incubated with various concentrations (25, 50, or 100 μg/mL) of G-Rb2 or G-Rd2 or the vehicle control for 40 min. Platelet aggregation was stimulated by 1 μg/mL collagen (A), 2 μg/mL collagen (B), 100 μM thrombin receptor activating peptide (TRAP) (C), 200 μM TRAP (D), 0.5 U/mL thrombin (E), 1 U/mL thrombin (F), 1 μM U46619 (G), or 2 μM U46619 (H), 0.5 μM PAF (I), or 1 μM PAF (J). Data was presented as mean ± SD (n=6). Statistical significance was analyzed by a one-way ANOVA followed by Dunnett's *t*-test. No significant differences were observed between the vehicle control and G-Rb2 or G-Rd2.




Figure S3. G-Rb2 and G-Rd2 do not exert cytotoxic effect on human platelets *in vitro*. Human PRP were pre-incubated with various concentrations (25, 50, or 100 µg/mL) of G-Rb2 or G-Rd2 or the vehicle control for 40 min. The leakage of lactate dehydrogenase (LDH) from platelets was measured to evaluate the cytotoxic effect of G-Rb2 and G-Rd2. The extent of LDH leakage was expressed as % of total enzyme activity measured in platelets completely lysed with 10% sodium dodecyl sulphate (SDS; positive control). Data was presented as mean \pm SD (n=5). Statistical significance was analyzed by a one-way ANOVA followed by Dunnett's *t*-test. No significant differences were observed between the vehicle control and G-Rb2 or G-Rd2.